Athebio AG, an innovation leader in the discovery and design of designed ankyrin repeat proteins (DARPins), today announced that it has entered into a collaboration agreement with US-based 3T Biosciences (“3T”), an immunotherapy company focused on discovering and developing next-generation therapies with curative potential based on its immune-response guided target discovery approach.
Under the agreement, Athebio will provide 3T with Athebody DARPins selected from its proprietary library against undisclosed peptide antigens presented on the cell surface by major histocompatibility complex (MHC) proteins. 3T may option the selected Athebody DARPins for further development.
“We are looking forward to working with the highly talented team at 3T Biosciences. We believe that Athebody DARPins have ideal properties to optimally recognize pMHC targets with very high specificity, which is crucial to be successful in this space,” said Patrik Forrer, CEO and Chairman at Athebio, and one of the inventors of the DARPin technology.